Cross-reactive dengue human monoclonal antibody prevents severe pathologies and death from Zika virus infections

JCI Insight

Volumn 2, Issue 8, 2017, Pages

  Kam, Yiu Wing ^a   Lee, Cheryl Yi Pin ^a,b   Teo, Teck Hui ^a   Howland, Shanshan W ^a   Amrun, Siti Naqiah ^a   Lum, Fok Moon ^a   See, Peter ^a   Kng, Nicholas Qing Rong ^a   Huber, Roland G ^c   Xu, Mei Hui ^a   Tan, Heng Liang ^d   Choo, Andre ^d,e   Maurer Stroh, Sebastian ^c,e,f   Ginhoux, Florent ^a   Fink, Katja ^a   Wang, Cheng I ^a   Ng, Lisa F P ^a,g,h   Rénia, Laurent ^a  

^a AGENCY FOR SCIENCE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c BIOINFORMATICS INSTITUTE   (Singapore)

^d AGENCY FOR SCIENCE   (Singapore)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^f NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^g NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^h UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85062412365     PISSN: None     EISSN: 23793708     Source Type: Journal    
DOI: 10.1172/jci.insight.92428     Document Type: Article

References (57)

1. Dick GW, Kitchen SF, Haddow AJ. Zika virus. I. Isolations and serological specificity. Trans R Soc Trop Med Hyg. 1952;46(5):509–520.
2. Lanciotti RS, et al. Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. Emerging Infect Dis. 2008;14(8):1232–1239.
3. Duffy MR, et al. Zika virus outbreak on Yap Island, Federated States of Micronesia. N Engl J Med. 2009;360(24):2536–2543.
4. Cao-Lormeau VM, et al. Zika virus, French Polynesia, South Pacific, 2013. Emerging Infect Dis. 2014;20(6):1085–1086.
5. Musso D, Nilles EJ, Cao-Lormeau VM. Rapid spread of emerging Zika virus in the Pacific area. Clin Microbiol Infect. 2014;20(10):O595–O596.
6. Campos GS, Bandeira AC, Sardi SI. Zika virus outbreak, Bahia, Brazil. Emerging Infect Dis. 2015;21(10):1885–1886.
7. Enfissi A, Codrington J, Roosblad J, Kazanji M, Rousset D. Zika virus genome from the Americas. Lancet. 2016;387(10015):227–228.
8. Hennessey M, Fischer M, Staples JE. Zika virus spreads to new areas - region of the Americas, May 2015-January 2016. MMWR Morb Mortal Wkly Rep. 2016;65(3):55–58.
9. Zika situation report. World Health Organization. http://www.who.int/emergencies/zika-virus/situation-report/8-december-2016/en/. Updated December 8, 2016. Accessed March 30, 2017.
10. Oehler E, et al. Zika virus infection complicated by Guillain-Barre syndrome-case report, French Polynesia, December 2013. Euro Surveill. 2014;19(9):e20720.
11. Cao-Lormeau VM, et al. Guillain-Barré syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet. 2016;387(10027):1531–1539.
12. Schuler-Faccini L, et al. Possible association between Zika virus infection and microcephaly - Brazil, 2015. MMWR Morb Mortal Wkly Rep. 2016;65(3):59–62.
13. Mlakar J, et al. Zika virus associated with microcephaly. N Engl J Med. 2016;374(10):951–958.
14. Cugola FR, et al. The Brazilian Zika virus strain causes birth defects in experimental models. Nature. 2016;534(7606):267–271.
15. Wu KY, et al. Vertical transmission of Zika virus targeting the radial glial cells affects cortex development of offspring mice. Cell Res. 2016;26(6):645–654.
16. Driggers RW, et al. Zika virus infection with prolonged maternal viremia and fetal brain abnormalities. N Engl J Med. 2016;374(22):2142–2151.
17. Simpson DI. Zika virus infection in man. Trans R Soc Trop Med Hyg. 1964;58:335–338.
18. Roth A, et al. Concurrent outbreaks of dengue, chikungunya and Zika virus infections - an unprecedented epidemic wave of mosquito-borne viruses in the Pacific 2012-2014. Euro Surveill. 2014;19(41):e20929.
19. Cardoso CW, et al. Outbreak of exanthematous illness associated with Zika, chikungunya, and dengue viruses, Salvador, Brazil. Emerging Infect Dis. 2015;21(12):2274–2276.
20. Dejnirattisai W, et al. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. Nat Immunol. 2016;17(9):1102–1108.
21. Barba-Spaeth G, et al. Structural basis of potent Zika-dengue virus antibody cross-neutralization. Nature. 2016;536(7614):48–53.
22. Priyamvada L, et al. Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proc Natl Acad Sci USA. 2016;113(28):7852–7857.
23. Swanstrom JA, et al. Dengue virus envelope dimer epitope monoclonal antibodies isolated from dengue patients are protective against Zika virus. MBio. 2016;7(4):e01123-16.
24. Dai L, et al. Structures of the Zika virus envelope protein and its complex with a flavivirus broadly protective antibody. Cell Host Microbe. 2016;19(5):696–704.
25. Xu M, et al. Plasmablasts generated during repeated dengue infection are virus glycoprotein-specific and bind to multiple virus serotypes. J Immunol. 2012;189(12):5877–5885.
26. Xu M, et al. A potent neutralizing antibody with therapeutic potential against all four serotypes of dengue virus. NPJ Vaccines. In press.
27. Wahala WM, Silva AM. The human antibody response to dengue virus infection. Viruses. 2011;3(12):2374–2395.
28. Mathew A, et al. B-cell responses during primary and secondary dengue virus infections in humans. J Infect Dis. 2011;204(10):1514–1522.
29. Fibriansah G, et al. A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins. Nat Commun. 2015;6:6341.
30. Kostyuchenko VA, et al. Structure of the thermally stable Zika virus. Nature. 2016;533(7603):425–428.
31. Halstead SB, Shotwell H, Casals J. Studies on the pathogenesis of dengue infection in monkeys. II. Clinical laboratory responses to heterologous infection. J Infect Dis. 1973;128(1):15–22.
32. Balsitis SJ, et al. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog. 2010;6(2):e1000790.
33. Halstead SB. Dengue antibody-dependent enhancement: knowns and unknowns. Microbiol Spectr. 2014;2(6):AID-0022-2014.
34. Acosta EG, Bartenschlager R. Paradoxical role of antibodies in dengue virus infections: considerations for prophylactic vaccine development. Expert Rev Vaccines. 2016;15(4):467–482.
35. Alvarez M, et al. Dengue hemorrhagic fever caused by sequential dengue 1-3 virus infections over a long time interval: Havana epidemic, 2001-2002. Am J Trop Med Hyg. 2006;75(6):1113–1117.
36. Hezareh M, Hessell AJ, Jensen RC, van de Winkel JG, Parren PW. Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1. J Virol. 2001;75(24):12161–12168.
37. Lazear HM, et al. A mouse model of Zika virus pathogenesis. Cell Host Microbe. 2016;19(5):720–730.
38. Miner JJ, et al. Zika virus infection during pregnancy in mice causes placental damage and fetal demise. Cell. 2016;165(5):1081–1091.
39. Yockey LJ, et al. Vaginal exposure to Zika virus during pregnancy leads to fetal brain infection. Cell. 2016;166(5):1247–1256.e4.
40. Zhao H, et al. Structural basis of Zika virus-specific antibody protection. Cell. 2016;166(4):1016–1027.
41. Stettler K, et al. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science. 2016;353(6301):823–826.
42. Sapparapu G, et al. Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice. Nature. 2016;540(7633):443–447.
43. Wang Q, et al. Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus. Sci Transl Med. 2016;8(369):369ra179.
44. Veljkovic V, Paessler S. Possible repurposing of seasonal influenza vaccine for prevention of Zika virus infection. F1000Res. 2016;5:190.
45. Halstead SB. Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res. 2003;60:421–467.
46. Guzman MG, Alvarez M, Halstead SB. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Arch Virol. 2013;158(7):1445–1459.
47. Goncalvez AP, Engle RE, St Claire M, Purcell RH, Lai CJ. Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci USA. 2007;104(22):9422–9427.
48. Beltramello M, et al. The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe. 2010;8(3):271–283.
49. Halstead SB. Licensed dengue vaccine: public health conundrum and scientific challenge. Am J Trop Med Hyg. 2016;95(4):741–745.
50. + T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes. J Virol. 2015;89(1):120–128.
51. Kam YW, et al. Early neutralizing IgG response to chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein. EMBO Mol Med. 2012;4(4):330–343.
52. Hamel R, et al. Biology of Zika virus infection in human skin cells. J Virol. 2015;89(17):8880–8896.
53. Howland SW, et al. Brain microvessel cross-presentation is a hallmark of experimental cerebral malaria. EMBO Mol Med. 2013;5(7):984–999.
54. Berman HM, et al. The Protein Data Bank. Nucleic Acids Res. 2000;28(1):235–242.
55. Krieger E, Koraimann G, Vriend G. Increasing the precision of comparative models with YASARA NOVA-a self-parameterizing force field. Proteins. 2002;47(3):393–402.
56. Teng TS, et al. Viperin restricts chikungunya virus replication and pathology. J Clin Invest. 2012;122(12):4447–4460.
57. Balm MN, Lee CK, Lee HK, Chiu L, Koay ES, Tang JW. A diagnostic polymerase chain reaction assay for Zika virus. J Med Virol. 2012;84(9):1501–1505.